solriamfetol   Click here for help

GtoPdb Ligand ID: 10342

Synonyms: ADX-N05 | ADXN05 | JZP-110 | JZP110 | Sunosi®
Approved drug
solriamfetol is an approved drug (FDA (2019), EMA (2020))
Compound class: Synthetic organic
Comment: Solriamfetol is a norepinephrine-dopamine reuptake inhibitor that was developed by Jazz Pharmaceuticals [1].
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/). All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 4
Hydrogen bond donors 2
Rotatable bonds 5
Topological polar surface area 78.34
Molecular weight 194.11
XLogP 0.49
No. Lipinski's rules broken 0

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

✖
Canonical SMILES NC(Cc1ccccc1)COC(=O)N
Isomeric SMILES N[C@H](Cc1ccccc1)COC(=O)N
InChI InChI=1S/C10H14N2O2/c11-9(7-14-10(12)13)6-8-4-2-1-3-5-8/h1-5,9H,6-7,11H2,(H2,12,13)/t9-/m1/s1
InChI Key UCTRAOBQFUDCSR-SECBINFHSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
No information available.
Summary of Clinical Use Click here for help
Solriamfetol produces wake-promoting effects, and is approved to treat adult patients with excessive daytime sleepiness/impaired wakefullness that is caused by narcolepsy or obstructive sleep apnea. Approval followed completion of Phase 3 trial NCT02348593 [4]. Solriamfetol has subsequently been investigated as a treatment for attention deficit hyperactivity disorder (ADHD) [3], based on the rationale that the drug shares sympathomimetic properties with drugs that are already used to treat ADHD (such as atomoxetine, viloxazine and guanfacine), and to potentiate a move away from prescribing stimulant drugs for ADHD [2].
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT02348593 "Twelve-week Study of the Safety and Efficacy of JZP-110 in the Treatment of Excessive Sleepiness in Narcolepsy" Phase 3 Interventional Jazz Pharmaceuticals 4
NCT05972044 A Study to Access the Efficacy and Safety of Solriamfetol in Subjects With ADHD (FOCUS) Phase 3 Interventional Axsome Therapeutics, Inc.
NCT04839562 A Controlled Study of Solriamfetol for Attention Deficit Hyperactivity Disorder (ADHD) in Adults Phase 2/Phase 3 Interventional Massachusetts General Hospital 3
NCT04789174 Solriamfetol's Effect on Cognitive Health in Apnea Participants During a Randomized Placebo-controlled Study Phase 4 Interventional Axsome Therapeutics, Inc. 5